PT1165126E - Processo para a preparação de uma vacina para o papilomavírus humanos com partículas semelhantes a vírus desagregadas e reagregadas - Google Patents

Processo para a preparação de uma vacina para o papilomavírus humanos com partículas semelhantes a vírus desagregadas e reagregadas Download PDF

Info

Publication number
PT1165126E
PT1165126E PT00918248T PT00918248T PT1165126E PT 1165126 E PT1165126 E PT 1165126E PT 00918248 T PT00918248 T PT 00918248T PT 00918248 T PT00918248 T PT 00918248T PT 1165126 E PT1165126 E PT 1165126E
Authority
PT
Portugal
Prior art keywords
vlps
hpv
buffer
process according
nacl
Prior art date
Application number
PT00918248T
Other languages
English (en)
Portuguese (pt)
Inventor
David B Volkin
Henryk Mach
Li Shi
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26824774&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT1165126(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of PT1165126E publication Critical patent/PT1165126E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PT00918248T 1999-03-26 2000-03-22 Processo para a preparação de uma vacina para o papilomavírus humanos com partículas semelhantes a vírus desagregadas e reagregadas PT1165126E (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12652899P 1999-03-26 1999-03-26
US09/524,624 US6245568B1 (en) 1999-03-26 2000-03-13 Human papilloma virus vaccine with disassembled and reassembled virus-like particles

Publications (1)

Publication Number Publication Date
PT1165126E true PT1165126E (pt) 2006-12-29

Family

ID=26824774

Family Applications (1)

Application Number Title Priority Date Filing Date
PT00918248T PT1165126E (pt) 1999-03-26 2000-03-22 Processo para a preparação de uma vacina para o papilomavírus humanos com partículas semelhantes a vírus desagregadas e reagregadas

Country Status (19)

Country Link
US (2) US6245568B1 (https=)
EP (1) EP1165126B1 (https=)
JP (1) JP4594534B2 (https=)
KR (1) KR20020013516A (https=)
AR (1) AR023166A1 (https=)
AT (1) ATE339222T1 (https=)
AU (1) AU778937B2 (https=)
CA (1) CA2368391C (https=)
CY (4) CY1105779T1 (https=)
DE (4) DE122007000032I1 (https=)
DK (1) DK1165126T3 (https=)
ES (1) ES2270822T3 (https=)
FR (1) FR07C0026I2 (https=)
LT (1) LTC1165126I2 (https=)
LU (3) LU91326I2 (https=)
NL (3) NL300269I2 (https=)
PT (1) PT1165126E (https=)
SI (1) SI1165126T1 (https=)
WO (1) WO2000057906A1 (https=)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6962777B1 (en) * 1997-09-05 2005-11-08 Medimmune, Inc. In vitro method for disassembly/reassembly of papillomavirus virus-like particles (vlps), homogeneous vlp and capsomere compositions produced by said methods; use thereof as vehicle for improved purification, and delivery of active agents
US7351533B2 (en) 1997-09-05 2008-04-01 Medimmune, Inc. In vitro method for disassmbly/reassembly of papillomavirus virus-like particles (VLPs). Homogeneous VLP and cavsomere compositions produced by said methods: use thereof as vehicle for improved purification, and delivery of active agents
CA2875298A1 (en) * 1999-12-09 2001-06-14 Medimmune, Inc. In vitro method for disassembly/reassembly of papillomavirus virus-like particles (vlps)
GB0118249D0 (en) * 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
CA2452720C (en) * 2001-07-26 2012-04-17 Chiron S.R.L. Vaccines comprising aluminium adjuvants and histidine
DE10137102A1 (de) * 2001-07-30 2003-02-27 Deutsches Krebsforsch Polyvalente Vakzine gegen durch Papillomaviren verursachte Erkrankungen, Verfahren zu deren Herstellung und deren Verwendung
US20060073530A1 (en) * 2001-08-15 2006-04-06 Olaf Schneewind Methods and compositions involving sortase B
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
WO2003068163A2 (en) * 2002-02-14 2003-08-21 Novavax, Inc. Optimization of gene sequences of chimeric virus-like particles for expression in insect cells
GB0206359D0 (en) * 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
GB0206360D0 (en) 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
DE10237639A1 (de) * 2002-08-13 2004-02-26 Martin-Luther-Universität Halle-Wittenberg Verfahren zur Herstellung von virusanalogen Partikeln durch in vitro-Assemblierung von Kapsomeren oder von Kapsomeren, an die biologisch aktive Makromoleküle gebunden sind, bei gleichzeitiger Verpackung der Makromoleküle
GB0220194D0 (en) * 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
EP2395073B1 (en) 2002-11-01 2017-09-06 GlaxoSmithKline Biologicals S.A. Drying process
WO2004056389A1 (en) 2002-12-20 2004-07-08 Glaxosmithkline Biologicals Sa Hpv-16 and -18 l1 vlp vaccine
US7858098B2 (en) * 2002-12-20 2010-12-28 Glaxosmithkline Biologicals, S.A. Vaccine
US20080131928A1 (en) * 2004-07-01 2008-06-05 Hiroshi Handa Viral Particle-Like Construct and Method of Forming the Same Under Physiological Conditions
JP5312799B2 (ja) * 2005-01-25 2013-10-09 ファイザー アイルランド ファーマシューティカルズ 収集精密ろ過における剪断保護剤
EP1907537A4 (en) * 2005-07-14 2010-11-10 Mayo Foundation Paramyxoviridae VIRUS PREPARATIONS
JPWO2007020871A1 (ja) * 2005-08-12 2009-02-26 アステラス製薬株式会社 デプシペプチド含有注射液
US20080268000A1 (en) * 2005-09-01 2008-10-30 Jose Luis Nuno Ayala Vaccine Stabilising Formula with Live Antigens for Use in Mass Vaccination Systems
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
US8962262B2 (en) * 2006-05-11 2015-02-24 Arbor Vita Corporation Method of protein extraction from cells
US9207240B2 (en) * 2007-11-14 2015-12-08 Arbor Vita Corporation Method of efficient extraction of protein from cells
JP5313231B2 (ja) * 2008-03-31 2013-10-09 森永乳業株式会社 耐熱性を付与する薬剤及び組成物
BR112012004699B1 (pt) 2009-09-03 2019-10-15 Becton, Dickinson And Company Métodos, composições e kits para lise química direta
KR101594228B1 (ko) 2010-08-23 2016-02-15 와이어쓰 엘엘씨 네이세리아 메닌기티디스 ｒＬＰ２０８６ 항원의 안정한 제제
NZ607224A (en) 2010-09-10 2014-11-28 Wyeth Llc Non-lipidated variants of neisseria meningitidis orf2086 antigens
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
MX359256B (es) 2012-03-09 2018-09-19 Pfizer Composiciones de neisseria meningitidis y metodos de las mismas.
WO2013139744A1 (en) 2012-03-18 2013-09-26 Glaxosmithkline Biologicals S.A. Method of vaccination against human papillomavirus
KR101559622B1 (ko) 2012-07-30 2015-10-13 중앙대학교 산학협력단 인유두종바이러스 바이러스 유사입자의 고효율 정제방법
US9802987B2 (en) 2013-03-08 2017-10-31 Pfizer Inc. Immunogenic fusion polypeptides
RU2662968C2 (ru) 2013-09-08 2018-07-31 Пфайзер Инк. Иммуногенная композиция против neisseria meningitidis (варианты)
AU2016221318B2 (en) 2015-02-19 2020-06-25 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
AU2018215585B2 (en) 2017-01-31 2022-03-17 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
US20200010850A1 (en) 2017-02-17 2020-01-09 The USA, as represeented by the Secretary, Dept. of Health and Human Services Efficient cell free production of papillomavirus gene transfer vectors
MX2020004151A (es) 2017-10-30 2020-08-13 Takeda Pharmaceuticals Co Detergentes compatibles con el medio ambiente para la inactivacion de virus envueltos en lipidos.
EP4034157A1 (en) 2019-09-27 2022-08-03 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
CN110987571A (zh) * 2019-12-31 2020-04-10 广州金域医学检验中心有限公司 一种单克隆多聚体m蛋白解聚方法
CN111812313B (zh) * 2020-06-22 2021-10-08 北京生物制品研究所有限责任公司 铝佐剂吸附型新型冠状病毒灭活疫苗中抗原的解离方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998034594A1 (en) * 1997-02-06 1998-08-13 Merck & Co., Inc. Thimerosal-free preservatives for vaccines
JP4598201B2 (ja) 1997-04-08 2010-12-15 メルク・シャープ・エンド・ドーム・コーポレイション 安定化ヒトパピローマウイルス製剤
AU755679B2 (en) 1997-07-03 2002-12-19 Medimmune, Llc Homogeneous human papilloma virus capsomere containing compositions, methods for manufacture,and the use thereof as diagnostic, prophylactic or therapy

Also Published As

Publication number Publication date
LU91327I9 (https=) 2019-03-01
FR07C0026I1 (https=) 2007-04-27
WO2000057906A1 (en) 2000-10-05
CY2007010I2 (el) 2009-11-04
NL300269I1 (nl) 2007-05-01
DE122007000032I1 (de) 2007-08-09
DK1165126T3 (da) 2007-01-08
DE122007000034I1 (de) 2007-08-09
JP4594534B2 (ja) 2010-12-08
CY1105779T1 (el) 2010-07-28
SI1165126T1 (sl) 2006-12-31
LU91327I2 (fr) 2007-05-14
DE60030698T2 (de) 2007-07-19
DE60030698D1 (de) 2006-10-26
NL300269I2 (nl) 2008-07-01
ATE339222T1 (de) 2006-10-15
NL300268I1 (nl) 2007-05-01
FR07C0026I2 (fr) 2012-08-03
LU91328I9 (https=) 2019-03-01
LU91328I2 (fr) 2007-05-14
CY2007009I2 (el) 2010-07-28
AR023166A1 (es) 2002-09-04
EP1165126B1 (en) 2006-09-13
CA2368391C (en) 2011-06-07
CY2007009I1 (el) 2010-07-28
CY2007010I1 (el) 2009-11-04
LTPA2007002I1 (lt) 2020-03-25
US20010021385A1 (en) 2001-09-13
AU3909300A (en) 2000-10-16
LTC1165126I2 (lt) 2020-04-27
LU91326I9 (https=) 2018-12-31
LU91326I2 (fr) 2007-05-14
JP2002540167A (ja) 2002-11-26
NL300270I1 (nl) 2007-05-01
EP1165126A1 (en) 2002-01-02
CY2007008I1 (el) 2009-11-04
DE122007000033I1 (de) 2007-08-09
KR20020013516A (ko) 2002-02-20
US6245568B1 (en) 2001-06-12
CA2368391A1 (en) 2000-10-05
AU778937B2 (en) 2004-12-23
CY2007008I2 (el) 2009-11-04
ES2270822T3 (es) 2007-04-16

Similar Documents

Publication Publication Date Title
PT1165126E (pt) Processo para a preparação de uma vacina para o papilomavírus humanos com partículas semelhantes a vírus desagregadas e reagregadas
EP1150712B1 (en) Human papilloma virus vaccine formulations
US12350375B2 (en) Method for obtaining efficient viral vector-based compositions for vaccination or gene therapy
RU2465007C2 (ru) Препарат вакцины на основе конъюгата никотин-носитель
JP2005538938A (ja) ワクチン
PL212981B1 (pl) Kompozycja szczepionkowa, sposób jej wytwarzania, zastosowanie mieszaniny HPV 16, HPV 18, HPV 31 i HPV VLP oraz stabilizowana kompozycja szczepionkowa
EP2485766A1 (fr) Excipient stabilisant pour vaccin a virus entiers inactives
HUT70982A (en) Hepatitis a vaccine
US20170182135A1 (en) Dry powder fibrin sealant
CN120475988A (zh) 免疫原性组合物及引发针对艰难梭菌的免疫应答的方法
CN121443277A (zh) 核酸-脂质纳米颗粒组合物、及其冻干制剂、制备方法和应用
HK40064104A (en) Stabilising excipient for vaccine with inactivated whole viruses
JP2001526292A (ja) クエン酸またはトリエタノールアミンおよびそれらの組合せを含むｄｎａ医薬製剤
KR20160098452A (ko) 바이로좀용의 개선된 제형
HK40126921A (zh) 免疫原性组合物及引发针对艰难梭菌的免疫应答的方法
EP0859846A1 (en) Rabies recombinant adenovirus
HK1167604A (en) Stabilising excipient for inactivated whole-virus vaccines